56 FOMO · ADS Group
Collaboration to support in-orbit pharmaceuticals manufacturing
AI Executive Summary
The UK Space Agency awarded BioOrbit a £250,000 feasibility study under its Unlocking Space Portfolio to define the regulatory pathway for manufacturing pharmaceuticals in orbit. BioOrbit, the MHRA, and the UK Space Agency will assess whether existing terrestrial pharmaceutical regulations apply to in-orbit production for patient use.